Tecrea is pleased to announce that we will be working with MedCity for the Collaborate to Innovate program !
Collaborate to Innovate is connecting 16 life sciences SMEs in areas of drug discovery, digital health, medical devices and diagnostics, with academics to address a specific challenge related to their products and services. They have been matched with leading researchers at Imperial College London, Kings College London, University College London, and Queen Mary University London, in up to £100,000 collaborations to develop and test their innovations.
MedCity exists to promote and grow life sciences investment, entrepreneurship, collaboration and industry in London, Cambridge, Oxford and the greater south east. It was launched in April 2014 by Imperial College Academic Health Science Centre, King’s Health Partners, UCLPartners and the Mayor of London. From drug discovery to devices, diagnostics and digital health, MedCity supports life sciences and healthcare companies large and small to do business in the golden triangle.
Tecrea and MedCity will work with UCL’s Dr Farlan Veraitch and his team within the Department of Biochemical Engineering. Together they will apply engineering expertise to scale production of Lentivirus-based therapies to meet the projected needs of the rapidly developing gene therapy market.
To find out more about this collaboration, visit this page.
To learn more about how Nanocin technology can help you in bioprocessing applications, please write to [email protected] and one of specialists will get back to you.